期刊
ADVANCED FUNCTIONAL MATERIALS
卷 28, 期 5, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.201703074
关键词
cancer therapy; doxorubicin; exosomes; GPI-anchored proteins; PH20
类别
资金
- National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [1420390]
- National Research Foundation of Korea (NRF) - Korea government [2017R1A2B2010292]
- KU-KIST Graduate School of Converging Science and Technology Program
- KIST Institutional Program
As biochemical and functional studies of membrane protein remain a challenge, there is growing interest in the application of nanotechnology to solve the difficulties of developing membrane protein therapeutics. Exosome, composed of lipid bilayer enclosed nanosized extracellular vesicles, is a successful platform for providing a native membrane composition. This study reports an enzymatic exosome, which harbors native PH20 hyaluronidase (Exo-PH20), which is able to penetrate deeply into tumor foci via hyaluronan degradation, allowing tumor growth inhibition and increased T cell infiltration into the tumor. This exosome-based strategy is developed to overcome the immunosuppressive and anticancer therapy-resistant tumor microenvironment, which is characterized by an overly accumulated extracellular matrix. Notably, this engineered exosome with the native glycosylphosphatidylinositol-anchored form of hyaluronidase has a higher enzymatic activity than a truncated form of the recombinant protein. In addition, the exosome-mediated codelivery of PH20 hyaluronidase and a chemotherapeutic (doxorubicin) efficiently inhibits tumor growth. This exosome is designed to degrade hyaluronan, thereby augmenting nanoparticle penetration and drug diffusion. The results thus show that this is a promising exosome-based platform that harbors not only a membrane-associated enzyme with high activity but also therapeutic payloads.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据